On October 1, 2021 Poseida Therapeutics, Inc. (Nadsaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, reported it will give two virtual poster presentations at the upcoming Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 36th Annual Meeting, being held in Washington, D.C., and virtually November 10-14, 2021 (Press release, Poseida Therapeutics, OCT 1, 2021, View Source [SID1234590653]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details on the two poster presentations are as follows. The full abstracts will be made available on the SITC (Free SITC Whitepaper) website on November 9, 2021.
Title: Memory Phenotype in Allogeneic Anti-BCMA CAR-T Cell Therapy (P-BCMA-ALLO1) Correlates with In Vivo Tumor Control
Presenter: Hubert Tseng, Ph.D., Poseida Therapeutics
Session Date/Time: ePoster Hall opens November 12, 2021, at 7:00am ET
Abstract Number: 147
Title: P-MUC1C-ALLO1: A Fully Allogeneic Stem Cell Memory T Cell (TSCM) CAR-T Therapy with Broad Potential in Solid Tumor
Presenter: Yan Zhang, Ph.D., Poseida Therapeutics
Session Date/Time: ePoster Hall opens November 12, 2021, at 7:00am ET
Abstract Number: 123
About P-BCMA-ALLO1
P-BCMA-ALLO1 is Poseida’s first fully allogeneic product candidate targeting B-cell maturation antigen (BCMA) for the treatment of relapsed/refractory multiple myeloma. In in vitro and in vivo preclinical studies, P-BCMA-ALLO1 showed effective targeted cancer cell killing and cytokine secretion, with similar or superior performance in anti-tumor efficacy compared to an autologous CAR-T therapy, P-BCMA-101. Inclusion of a proprietary "booster molecule" in the allogeneic manufacturing process further improves expansion of gene-edited cells and may potentially enable production of hundreds of patient doses from a single manufacturing run, thereby reducing the manufacturing cost per dose into the same range as that of a monoclonal antibody. In August 2021, Poseida announced that its Investigational New Drug (IND) application for P-BCMA-ALLO1 received clearance from the U.S. Food and Drug Administration (FDA). Additional information about the Phase 1 study is available at www.clinicaltrials.gov using identifier: NCT04960579.
About P-MUC1C-ALLO1
P-MUC1C-ALLO1 is an allogeneic CAR-T product candidate in preclinical development with the potential to treat a wide range of solid tumors derived from epithelial cells, including breast and ovarian cancers, as well as other cancers expressing a cancer-specific form of the Mucin 1 protein, or MUC1C. We have designed P-MUC1C-ALLO1 to be fully allogeneic, with genetic edits to eliminate or reduce both host-vs-graft and graft-vs-host alloreactivity. We have demonstrated the elimination of tumor cells to undetectable levels in two preclinical models of breast cancer and a preclinical model of ovarian cancer.